Tissue Diagnostics Market (2022-2029)
The Tissue Diagnostics Market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% from 2022 to 2029.
- Published
- Nov 2022
- Pages
- 226
- Format
- PDF + Excel
- Report ID
- MRHC - 104268
- Base year
- 2021
- 2029 · FORECAST
- $8.52B
- 2029
- $8.52B
- CAGR 2022–2029
- 7.4%
2021 baseline · 2022–2029 forecast at 7.4% CAGR · hover a bar for the value
Key highlights
Based on product type, in 2022, the consumables segment is expected to account for the largest share
Based on technique, in 2022, the immunohistochemistry (IHC) segment is expected to account for the largest share
Based on application, in 2022, the breast cancer segment is expected to account for the largest share
Based on end user, in 2022, the hospitals & diagnostic laboratories segment is expected to account for the largest share
Asia-Pacific: Lucratively Growing Regional Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2021 |
| Estimated Year | 2022 |
| Forecast Period | 2022–2029 |
| Market Size (2029) | USD 8.52 billion |
| CAGR (2022–2029) | 7.4% |
| Format | PDF, Excel & Cloud Portal · 226 pages |
| Segments Covered | By Product Type: Consumables, Kits & Reagents, Antibodies, Instruments, Slide Staining Systems, Slide Scanners, Tissue Processors, Tissue Microarrays, Other Instruments · By Technique: Immunohistochemistry (IHC), In-situ Hybridization (ISH), Digital Pathology, H&E and Special Staining, Molecular Diagnostics, Other Techniques · By Application: Breast Cancer, Lung Cancer, Colorectal and Gastrointestinal Cancer, Prostate Cancer, Lymphoma, Other Applications · By End User: Hospitals & Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Contract Research Organizations · By Technology: Digital Pathology, IHC, ISH, H&E Staining · By Cancer Type: Breast, NSCLC, Colorectal, Prostate |
| Countries Covered | Europe (RoE), Asia-Pacific (RoAPAC) |
| Key Companies | F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, QIAGEN N.V., Abcam plc, Agilent Technologies, Inc., Merck KGaA, Sakura Finetek Japan Co., Ltd., Cell Signaling Technology, Inc. |
Report overview
Segments covered: product type, technique, application, end user, technology, cancer type. Regions: Europe, Asia-Pacific.
Biopsy, a procedure for detecting cancer, is recommended when an initial diagnostics test suggests an abnormality in an area of tissue in the body. It involves removing a small amount of abnormal tissue, which is sent to a laboratory for examination under a microscope. This process is called tissue diagnosis. Tissue diagnostics involves the study of tissue to diagnose disease and determine whether the tissue is cancerous, its type, and the characteristics of observed cancer. Tissue diagnostics uses instruments such as slide staining systems, slide scanners, tissue processing systems, embedding systems, and microarray.
The tissue diagnostics market is growing due to the rising prevalence of cancer globally, the availability of biomarkers and research on biomarkers, recommendations for cancer screening, the growing number of clinical trials for oncology drugs, and the availability of tissue-based companion diagnostics. Furthermore, the rising focus on personalized healthcare and the advent of digital pathology and tissue diagnosis automation offer significant market growth opportunities.
Report infographic
COVID-19 Impact Assessment
The COVID-19 pandemic negatively impacted the tissue diagnostics market due to the decrease in the number of people getting screened for cancer during the pandemic. In the U.S., screenings for cancers of the breast, colon, and cervix dropped by 94%, 86%, and 94% between 20th January 2020 and 21st April 2020, respectively (Source: Epic Research Journal). Many screening facilities closed temporarily, while others faced severe staffing shortages. Similarly, in Europe, cancer services were disrupted by 50% by the end of 2021 (Source: Global Pulse Survey). People were afraid to go to hospitals and other medical facilities for non-emergency procedures due to the fear of COVID-19, which negatively affected cancer screening practices.
In 2020, during the first lockdown, national screening programs for many cancers, such as colorectal carcinoma, breast carcinoma and cervical carcinoma, were paused in many countries. For instance,
- In May 2020, the Government of India suspended the population-based screening as part of the national program based on the risk associated with oral cavity examination. The Government launched the country’s first national cancer screening program in 2016 under the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS).
- In March 2020, the Scottish Government temporarily suspended the national screening programs for cervical, breast, and bowel cancers.
Thus, there was a decline in the screening rate, which affected the tissue diagnostics market. Apart from this, there were temporary supply chain disruptions due to lockdowns and travel restrictions, which also negatively affected the tissue diagnostics market.
Market dynamics
1 factors across 1 forceThe Advent of Digital Pathology and Automation in Tissue Diagnostics is the Trend Prevailing in the Market
Automated tissue diagnostics are gaining acceptance due to the improved technical performance of the assays, which reduces reagent costs and assay time. Management of huge data and the lack of availability of skilled pathologists also contribute to the need for automation in tissue diagnostic systems. Innovations in the automation of staining equipment and novel platforms such as digital immunohistochemistry (IHC) are among the developments in tissue diagnostics.
Additionally, advanced laboratory information system (LIS) is also emerging in the field of tissue diagnostics. In the tissue diagnostics market, the development of end-to-end integrated workflow solutions will lead to the expansion of the market in the future. This can be achieved by collaborating with anatomic pathology LIS (APLIS) vendors and partnering with instrument distributors in emerging countries.
Automating the process is necessary as most of the workflow in a histology laboratory is manual. Many diagnostic equipment manufacturers are launching automated platforms to improve laboratory efficiency, reduce time, and provide pathologists with advanced systems for diagnosis. A few examples are mentioned below:
- In May 2022, Leica Biosystems (Germany) launched its BOND-PRIME, an advanced staining solution to expand diagnostic productivity in laboratories. This system enables lab technicians to load any slides in any combination, with any reagent, at any time.
- In August 2021, Lumito AB (Sweden) launched its instrument and staining reagents based on up-converting nanoparticles (UCNPs) used in tissue diagnostics. This provides visual depictions of tissue samples as input for making a diagnosis to the pathologists. The technology has several application areas, but the company initially focused on tissue diagnostics and digital pathology.
Table of contents
12 chapters · 100 sections · 226 pages · click to expandSegmental analysis
| Segment | Largest share (2022) | Fastest growth (2022–2029) |
|---|---|---|
| By Product Type | Consumables | — |
| By Technique | Immunohistochemistry (IHC) | — |
| By Application | Breast cancer | — |
| By End User | Hospitals & diagnostic laboratories | — |
By Product Type
- The consumables segment is expected to account for the largest share
- Diagnostic consumables are one-time or limited-use items used during diagnosis.
- The large market share of this segment is attributed to the recurring requirement for consumables and research in developing novel reagents and other consumables.
- For example, the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), a collaborative consortium of academic and private-sector investigators, focuses on the systematic discovery, development, and validation of biomarkers and imaging methods to detect early-stage cancers and to assess the risk associated to developing cancer.
- Such research studies are driving the demand for consumables for tissue diagnostics.
By Technique
- The immunohistochemistry (IHC) segment is expected to account for the largest share
- Immunohistochemistry provides variations between different types of tumors, which is why it is preferred over conventional enzyme staining techniques, especially in cancer screenings.
- Thus, the high adoption of cancer screening, technological developments in immunohistochemistry, and availability of reimbursement policies for IHC-based tests contribute to the large market share of this segment.
By Application
- The breast cancer segment is expected to account for the largest share
- The prevalence of breast cancer is high and rising gradually across the globe.
- According to WHO, in 2020, 2.3 million women were globally diagnosed with breast cancer.
- Thus, the high prevalence of breast cancer and the presence of funding programs to support research and early screening of breast cancer are the factors contributing to the large market share of this segment.
- For instance, in October 2021, The Breast Cancer Research Foundation (BCRF) announced a USD 47.5 million commitment to fund breast cancer research from 2021–2022.
By End User
- The hospitals & diagnostic laboratories segment is expected to account for the largest share
- The high flow of patient pool to the hospitals & diagnostic laboratories due to the rising prevalence of cancer globally and an increase in the budget for adopting advanced technologies contribute to the large market share of this segment.
Geographic analysis
Asia-Pacific
The growth of this regional market is attributed to the growing cancer prevalence, improving healthcare services, rising healthcare spending, and early cancer screening in Asia-Pacific. Asia-Pacific: Lucratively Growing Regional Market
Competitive landscape
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- QIAGEN N.V.
- Abcam plc
- Agilent Technologies, Inc.
- Merck KGaA
- Sakura Finetek Japan Co., Ltd.
- Cell Signaling Technology, Inc.
Frequently asked questions
This study offers a detailed assessment of the tissue diagnostics market, including the market size & forecast for various segmentations such as product type, technique, application, and end user. This report also involves the value analysis of various segments and sub-segments of the tissue diagnostics market at the regional and country levels.
Cite this report
Meticulous Research. (2022). Tissue Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2022-2029) (Report No. MRHC - 104268). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/tissue-diagnostics-market-4971